| ||
| ImmunoGen Reports Positive Data On IMGN901 In Treatment Of Multiple Myeloma RTT News IMGN901 is in development by ImmunoGen for the treatment of CD56-expressing cancers, which include small-cell lung cancer, multiple myeloma, Merkel cell carcinoma, and ovarian cancer. The company reported data from a trial designed to assess ... See all stories on this topic » | ||
| Continued Use Of Eli Lilly's Alimta Prevents Lung Cancer From Worsening - Update RTT News ... the company said Alimta in the continuation maintenance setting met its primary end point of progression-free survival for patients with a specific type of lung cancer called advanced non-squamous non-small cell lung cancer or NSCLC. ... See all stories on this topic » | ||
| EURTAC Interim Analysis of Erlotinib vs. Chemotherapy in Advanced NSCLC ... Monthly Prescribing Reference Rafael Rosell, MD, PhD, from the Spanish Lung Cancer Group; Catalan Institute of Oncology, Barcelona, Spain, and colleagues, performed a prospective, randomized Phase 3 study comparing erlotinib 150mg/day with platinum-based CT in chemonaive patients ... See all stories on this topic » | ||
| Eli Lilly Chemo Drug Delays Some Lung Cancer Progression NASDAQ Alimta is a chemotherapy that blocks three enzymes that are used by cancer cells to grow. The drug is already approved by the FDA for newly diagnosed patients with advanced nonsquamous non-small cell lung cancer to be used with another chemotherapy, ... See all stories on this topic » | ||
| Therapy Slows Progression of Advanced Lung Cancer Global Medical News Network Pemetrexed maintenance therapy following pemetrexed plus cisplatin induction reduced the risk of progression by 38% in patients with advanced nonsquamous non-small cell lung cancer in the phase III PARAMOUNT trial. Trial was presented at 2011 ASCO. See all stories on this topic » | ||
| Eli Lilly Reports Results Of Phase-III Study On Cancer Drug Alimta RTT News ... Sunday said 'Paramount', the phase-III study evaluating cancer drug Alimta in the continuation maintenance setting met its primary endpoint of progression-free survival for patients with advanced nonsquamous non-small cell lung cancer (NSCLC). ... See all stories on this topic » | ||
| Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non ... 7thSpace Interactive (press release) The expression and genetic methylation patterns of NMDAR2B in non-small cell lung cancer (NSCLC) are unknown. Methods: The relationship between gene methylation and expression of NMDAR2B was analyzed in NSCLC cell lines (N = 9) and clinical tissues (N ... See all stories on this topic » | ||
| Drugs To Watch At ASCO 2011 istockAnalyst.com (press release) Lilly's (LLY) Alimta has been able to capture market share in non-small cell lung cancer (NSCLC) thanks to impressive activity as second line or maintenance therapy (discussed in my ASCO 2009 write up) in a large subset (70%) of patients. ... See all stories on this topic » |
| ||
| Metagenes Associated with Survival in Non-Small Cell Lung Cancer AbstractNSCLC (non-small cell lung cancer) comprises about 80% of all lung cancer cases worldwide. Surgery is most effective treatment for patients with ... www.la-press.com/metagenes-associated-with-survival-in-non-... | ||
| Non-Small Cell Lung Cancer - Latest News Latest news and links for Non-Small Cell Lung Cancer. non-small-cell-lung-cancer.frecosse.com/ | ||
| Brain metastasis as the first manifestation of small cell lung ... Small cell lung cancer is commonly regarded as an old age related disease. www.docguide.com/brain-metastasis-first-manifestation-small-... | ||
| Clinical Aspects of Inflammation in Non-small Cell Lung Cancer Search and download thousands of Swedish university dissertations (essays). Full text. Free. Dissertation: Clinical Aspects of Inflammation in Non-small ... www.dissertations.se/dissertation/e38454c3fb/ |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment